Belyntic GmbH
Belyntic GmbH is a Berlin-based biotech company specializing in the development of novel T cell-inducing immunotherapies and vaccines for infectious diseases and cancer.
About
Belyntic GmbH is an early-stage preclinical biotech company focused on developing highly effective T cell-inducing vaccines and immunotherapies against viral and bacterial infectious diseases, as well as cancer. The company leverages its proprietary T-Fender platform technology, which uses self-adjuvant, self-aggregating synthetic long peptides and AI-based design, to create vaccines that elicit robust cellular immune responses. Belyntic's main focus is on protecting vulnerable patient populations, such as transplant recipients and immunocompromised individuals, from the reactivation of latent infections like cytomegalovirus (CMV) and John Cunningham virus (JCV). The company is also involved in collaborations with academic institutions such as Charité Berlin and has a history of successful technology transfers and strategic development in the biotech industry.
Products & Services
- T-Fender vaccine platform
- Therapeutic and preventive vaccines against viral infections (e.g., CMV, JCV)
- Therapeutic and preventive vaccines against bacterial infections
- Development of immunotherapeutic drug candidates based on T cell induction
- Collaborative research and biotechnology partnerships
Use Cases & Case Studies
- Development of a new CMV vaccine for transplant recipients
- Therapeutic vaccine research for John Cunningham virus (JCV) reactivation and progressive multifocal leukoencephalopathy (PML)
Partnerships & Collaborations
- Collaboration with Charité Berlin (Prof. Leif E. Sander)
Awards & Recognition
- Pitch-session winner at Prague Bio 2023